Compare Neurocrine Biosciences Inc (NBIX) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Okta, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Okta, Inc. trades at $141.58 (market cap $25.79B). The key difference: Okta, Inc. is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Okta, Inc. nearer its low. Which is the better fit depends on your goals.
| NBIX | OKTA | |
|---|---|---|
Market Cap | $17.40B | $25.79B |
Sector | Health | Technology |
52-Week High | $180.55 | $154.62 |
52-Week Low | $123.10 | $62.93 |
Enterprise Value | $16.49B | $23.62B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
